<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="13198"><DrugName>SDZ-GLC-756</DrugName><DrugSynonyms><Name><Value>SDZ-GLC-756</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>149328-94-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesSecondary><Company id="23137">Novartis AG</Company><Company id="24572">Sandoz Pharma Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="13198" type="Drug"><TargetEntity id="231811" type="siDrug">GLC-756</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="134" type="ciIndication"><TargetEntity id="H40" type="ICD10"/><TargetEntity id="365" type="ICD9"/><TargetEntity id="10018304" type="MEDDRA"/><TargetEntity id="D005901" type="MeSH"/><TargetEntity id="-1306155249" type="omicsDisease"/><TargetEntity id="777" type="siCondition"/></SourceEntity><SourceEntity id="149" type="Action"><TargetEntity id="131" type="Mechanism">Dopamine D2 Agonists</TargetEntity></SourceEntity><SourceEntity id="148" type="Action"><TargetEntity id="124" type="Mechanism">Dopamine D1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00632" type="ciTarget"><TargetEntity id="18259311118123" type="siTarget">D(1A) dopamine receptor</TargetEntity><TargetEntity id="943" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00633" type="ciTarget"><TargetEntity id="80088336218133" type="siTarget">D(2) dopamine receptor</TargetEntity><TargetEntity id="8168" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="134">Glaucoma</Indication></IndicationsSecondary><ActionsPrimary><Action id="149">Dopamine D2 receptor agonist</Action><Action id="148">Dopamine D1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="15137">Topical antiglaucoma agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>S1E2</Code><Name>Miotics and antiglaucoma preparations, topical</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-17T10:04:28.000Z</LastModificationDate><ChangeDateLast>2009-04-17T12:13:37.000Z</ChangeDateLast><AddedDate>1996-09-06T10:08:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; (formerly Sandoz) has discontinued development of &lt;ulink linkID="13198" linkType="Drug"&gt;SDZ-GLC-756&lt;/ulink&gt; [&lt;ulink linkID="347827" linkType="reference"&gt;347827&lt;/ulink&gt;], a dopamine D1 antagonist and D2 agonist, for the potential treatment of glaucoma. It had reached phase II clinical trials [&lt;ulink linkID="218747" linkType="reference"&gt;218747&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Clinical trials had shown that the acute instillation of 0.1% &lt;ulink linkID="13198" linkType="Drug"&gt;SDZ-GLC-756&lt;/ulink&gt; lowers the IOP of healthy volunteers and patients with glaucoma. Although a contralateral effect was present, no side effects, other than a transient hyperemia, were observed [&lt;ulink linkID="261946" linkType="reference"&gt;261946&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="134">Glaucoma</Indication><StatusDate>1999-11-24T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24572">Sandoz Pharma Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="134">Glaucoma</Indication><StatusDate>1995-12-01T00:00:00.000Z</StatusDate><Source id="218747" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00632"><Name>Dopamine D1 receptor</Name><SwissprotNumbers><Swissprot>O02664</Swissprot><Swissprot>O77680</Swissprot><Swissprot>P18901</Swissprot><Swissprot>P21728</Swissprot><Swissprot>P35406</Swissprot><Swissprot>P42288</Swissprot><Swissprot>P42289</Swissprot><Swissprot>P50130</Swissprot><Swissprot>Q61616</Swissprot><Swissprot>Q95136</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00633"><Name>Dopamine D2 receptor</Name><SwissprotNumbers><Swissprot>O73810</Swissprot><Swissprot>P14416</Swissprot><Swissprot>P20288</Swissprot><Swissprot>P52702</Swissprot><Swissprot>P60026</Swissprot><Swissprot>P61168</Swissprot><Swissprot>P61169</Swissprot><Swissprot>Q9GJU1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CN1C[C@@H](C[C@H]2[C@H]1Cc3cccc(c3C2)O)CSc4ccccn4</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></drugRecordOutput>